Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"

Supplemental material for Lebwohl et al, "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)," JAAD, 2019.

本补充材料为Lebwohl等人2019年发表于《美国皮肤病学会杂志》（Journal of the American Academy of Dermatology，缩写JAAD）的研究《银屑病（Psoriasis）患者代谢综合征（Metabolic Syndrome）状态不影响替达珠单抗（Tildrakizumab）的疗效与安全性——两项三期随机对照试验（Phase 3 Randomized Controlled Studies）reSURFACE 1与reSURFACE 2的事后分析（Post Hoc Analysis）》。